Paragon 28 (FNA) Reports Prelim Q4 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021
January 10, 2022 6:00 AM ESTENGLEWOOD, Colo.--(BUSINESS WIRE)-- Paragon 28, Inc. (NYSE: FNA) (Paragon 28 or P28), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2021.
Preliminary unaudited revenue for the fourth quarter of 2021 is expected to be in a range of $42.3 to $42.7 million, reflecting growth of 20.7% to 21.8% compared to revenue of $35.1 million for the fourth quarter of 2020.
Preliminary unaudited revenue for the full-year of 2021 is expected to be in a range of $147.0 to $147.4 million, reflecting... More
